Linear polymers of β and γ cyclodextrins with a polyglutamic acid backbone as carriers for doxorubicin

Cyclodextrins have been used to encapsulate drugs improving their stability and efficiently regulating their release. Polymeric nanoparticles containing cyclodextrins are currently undergoing clinical trials as nanotherapeutics. In this context, we have synthesized new linear polymers based on polyglutamic acid with pendant β- or γ-cyclodextrins, using a high yield reaction route. The new polymers with an average number of about 17 cyclodextrin cavities were characterized (NMR, MALDI-MS, DLS) and tested as carriers of doxorubicin in human tumor cells. They can include doxorubicin, and the inclusion complexes show antiproliferative activity in human tumor cells.